Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis
- PMID: 30728207
- PMCID: PMC6684229
- DOI: 10.1183/13993003.02237-2018
Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis
Abstract
A clinically useful model to prognose onset of respiratory insufficiency in amyotrophic lateral sclerosis (ALS) would inform disease interventions, communication and clinical trial design. We aimed to derive and validate a clinical prognostic model for respiratory insufficiency within 6 months of presentation to an outpatient ALS clinic.We used multivariable logistic regression and internal cross-validation to derive a clinical prognostic model using a single-centre cohort of 765 ALS patients who presented between 2006 and 2015. External validation was performed using the multicentre Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database with 7083 ALS patients. Predictors included baseline characteristics at first outpatient visit. The primary outcome was respiratory insufficiency within 6 months, defined by initiation of noninvasive ventilation, forced vital capacity (FVC) <50% predicted, tracheostomy, or death.Of 765 patients in our centre, 300 (39%) had respiratory insufficiency or death within 6 months. Six baseline characteristics (diagnosis age, delay between symptom onset and diagnosis, FVC, symptom onset site, amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) total score and ALSFRS-R dyspnoea score) were used to prognose the risk of the primary outcome. The derivation cohort c-statistic was 0.86 (95% CI 0.84-0.89) and internal cross-validation produced a c-statistic of 0.86 (95% CI 0.85-0.87). External validation of the model using the PRO-ACT cohort produced a c-statistic of 0.74 (95% CI 0.72-0.75).We derived and externally validated a clinical prognostic rule for respiratory insufficiency in ALS. Future studies should investigate interventions on equivalent high-risk patients.
Copyright ©ERS 2019.
Conflict of interest statement
Conflict of interest: J. Ackrivo has nothing to disclose. Conflict of interest: J. Hansen-Flaschen has nothing to disclose. Conflict of interest: E.P. Wileyto has nothing to disclose. Conflict of interest: R.J. Schwab has nothing to disclose. Conflict of interest: L. Elman has nothing to disclose. Conflict of interest: S.M. Kawut has nothing to disclose.
Figures
Comment in
-
Predicting respiratory failure in amyotrophic lateral sclerosis: recruiting a few good pulmonologists.Eur Respir J. 2019 Apr 18;53(4):1900360. doi: 10.1183/13993003.00360-2019. Print 2019 Apr. Eur Respir J. 2019. PMID: 31000666 No abstract available.
-
Predicting respiratory failure in amyotrophic lateral sclerosis: still a long way to go.Eur Respir J. 2019 Aug 1;54(2):1901065. doi: 10.1183/13993003.01065-2019. Print 2019 Aug. Eur Respir J. 2019. PMID: 31371441 No abstract available.
-
Predicting respiratory failure in amyotrophic lateral sclerosis: still a long way to go.Eur Respir J. 2019 Aug 1;54(2):1901221. doi: 10.1183/13993003.01221-2019. Print 2019 Aug. Eur Respir J. 2019. PMID: 31371442 Free PMC article. No abstract available.
References
-
- Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017; 377: 162–172. - PubMed
-
- Yeo L, Lynch C, Hardiman O. Validating population-based registers for ALS: how accurate is death certification? J Neurol 2010; 257: 1235–1239. - PubMed
-
- Spataro R, Re Lo M, Piccoli T, et al. Causes and place of death in Italian patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2010; 122: 217–223. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous